Lisata's Tender Offer Expires with 66.8% Tendered, But Kuva Labs Fails to Fund — Deal in Jeopardy
LSTA sits 73% above its 52-week low of $1.81.
Summary
Lisata's tender offer expired with enough shares tendered, but buyer Kuva Labs cannot fund the deal. Lisata is exploring legal options as the acquisition hangs in the balance.
Key Events · M&A and Partnerships · LSTA
-
Tender Offer Expires with 66.8% Tendered
As of the July 20, 2026 expiration, approximately 6,095,868 shares (66.8% of outstanding) were validly tendered, satisfying the minimum tender condition.
-
Kuva Labs Fails to Fund Acquisition
Parent Kuva Labs has been unable to obtain sufficient financing to fund the offer and has not accepted the tendered shares or confirmed when it will be able to do so.
-
Lisata Evaluates Legal Remedies
Lisata is evaluating its rights and remedies against Purchaser for failing to promptly accept and pay for the tendered shares, though this does not yet change the board's recommendation.
-
Deal Uncertainty Compounds Going-Concern Risk
Lisata previously disclosed substantial doubt about its ability to continue as a going concern; the failed funding of this acquisition removes a critical lifeline.
Analysis · LSTA · Life Sciences
The tender offer for Lisata Therapeutics expired on July 20 with 66.8% of shares validly tendered, meeting the minimum condition. However, Kuva Labs has been unable to secure financing and has not accepted the shares or paid. Lisata is now evaluating its legal remedies. This is a critical breakdown of a previously agreed acquisition, leaving shareholders in limbo and the company's future uncertain — especially given Lisata's existing going-concern warning.
At the time of this filing, LSTA was trading at $3.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.1M. The 52-week trading range was $1.81 to $5.07. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.